GlassScriptPhysician profile
Michael R Alavian
NPI 1538489364
$6,089.10
in general payments reported to CMS, 2019-2025
33 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $549 · 2021: $441 · 2022: $1,134 · 2023: $988 · 2024: $1,067 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $63.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.22 |
| Education | $63.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,076.16 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Pfizer INC. | $704.31 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $504.11 | 2023-2025 | Gemtesa, Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $490.67 | 2021-2025 | |
| Abbvie INC. | $382.21 | 2019-2025 | Lupron Depot, Botox |
| Janssen Biotech, INC. | $371.54 | 2019-2025 | Erleada, Akeega, Balversa |
| Endo Pharmaceuticals INC. | $287.35 | 2019-2024 | Aveed, Xiaflex |
| Teleflex LLC | $261.08 | 2022-2025 | Urolift, Barrigel |
| Progenics Pharmaceuticals, INC. | $201.61 | 2022-2025 | Pylarify |
| Antares Pharma, INC. | $178.96 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Tolmar, INC. | $166.69 | 2023-2025 | Jatenzo, Eligard |
| Tolmar Pharmaceuticals, INC. | $161.23 | 2019-2022 | |
| Endo USA, INC. | $141.46 | 2024-2025 | Aveed, Xiaflex |
| Coloplast Corp | $137.54 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $132.63 | 2021-2025 | Prolaris |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $117.95 | 2020 | |
| Dendreon Pharmaceuticals LLC | $115.09 | 2019-2025 | Provenge |
| Olympus America INC. | $88.24 | 2022-2024 | Itind System |
| Verity Pharmaceuticals INC. | $77.18 | 2024 | Trelstar |
| Dentsply Ih Ab | $76.41 | 2023 | Lofric |
| Allergan, INC. | $68.04 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $59.40 | 2024-2025 | Adstiladrin |
| 180 Medical, INC. | $46.51 | 2022-2024 | |
| Myovant Sciences INC. | $35.88 | 2022 | |
| Telix Pharmaceuticals | $33.11 | 2023-2024 | Illuccix |
| Halozyme INC | $31.48 | 2023 | |
| Profound Medical Corp. | $30.00 | 2025 | Tulsa-Pro |
| Blue Earth Diagnostics | $28.13 | 2025 | Posluma |
| C. R. Bard, INC. & Subsidiaries | $24.62 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.76 | 2022 | |
| Becton, Dickinson and Company | $13.83 | 2019 | |
| Acerus Pharmaceuticals Corporation | $13.38 | 2021 | |
| Janssen Pharmaceuticals, INC | $8.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Alavian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.